In a case that was billed as profits versus patients, India’s Supreme Court dismissed a petition in which Roche sought to ...

Imagine a child born in a family with a rare disease, whose treatment would cost more than 17 crore for a single dose. The ...

The Muscular Dystrophy Association (MDA) today kicked off its largest annual MDA Holiday Retail Campaign, spanning thousands of retail ...

Novartis is seeking to repurpose its investigational oral spinal muscular atrophy (SMA) drug branaplam to treat Huntington's disease, the Swiss drugmaker said on Wednesday, as it plans a clinical ...

Nearly all children with spinal muscular atrophy who started on Evrysdi before symptom onset are walking after three years, ...

The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene ...

Gene therapy is linked to better nonmotor outcomes in spinal muscular atrophy type 1 compared to first-line nusinersen, new ...

For people with spinal muscular atrophy, physical therapy can help support mobility, strength, and quality of life, regardless of SMA type.

The Rare Disease Therapeutics Market is experiencing an unprecedented wave of innovation, driven by gene therapies, RNA-based ...

The Supreme Court upheld Delhi HC's interim order allowing Natco Pharma to manufacture and sell a generic version of Roche's ...

In a huge setback for Swiss pharma major Roche, the Supreme Court on Friday dismissed its petition challenging a Delhi High ...

Delhi High Court allows Natco Pharma to continue selling its generic Risdiplam for spinal muscular atrophy, dismissing ...